T1 mapping and amyloid cardiomyopathy: how much better can it get?

Affiliations

¹ University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK First Department of Cardiology, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece theo.karamitsos@cardiov.ox.ac.uk.
² University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.

Editorial

Theodoros D Karamitsos et al. Eur Heart J. 2015.

. 2015 Jan 21;36(4):203-5.

doi: 10.1093/eurheartj/ehu442. Epub 2014 Nov 16.

¹ University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK First Department of Cardiology, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece theo.karamitsos@cardiov.ox.ac.uk.
² University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK.

No abstract available

Comment on

T1 mapping and survival in systemic light-chain amyloidosis.
Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. Banypersad SM, et al. Eur Heart J. 2015 Jan 21;36(4):244-51. doi: 10.1093/eurheartj/ehu444. Epub 2014 Nov 16. Eur Heart J. 2015. PMID: 25411195 Free PMC article.